SLU-PP-332
Aliases: SLUPP332 · "Exercise mimetic"
Last verified: 2026-09-23
The short version
An ERR (estrogen-related receptor) α/β/γ agonist — "exercise in a pill": in mice increases fat oxidation, endurance and aerobic capacity without movement. Key fact: No controlled human trials exist. Everything known about SLU-PP-332 in humans comes from indirect sources and self-reports. Status: preclinical. Not approved; research chemical.
Identity & type
- Molecular type
- mali molekul
- Origin
- An ERR (estrogen-related receptor) α/β/γ agonist — "exercise in a pill": in mice increases fat oxidation, endurance and aerobic capacity without movement.
Mechanism of action
Pan-ERR agonism → muscle reprogramming toward oxidative (slow-twitch) profile; increased mitochondrial biogenesis.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for SLU-PP-332. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Preclinical only; no human doses. Early experiences: described as "cardio without cardio" — better endurance and less fatigue in training; very little data, long-term picture unknown.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Early experiences: described as "cardio without cardio" — better endurance and less fatigue in training; very little data, long-term picture unknown.
Protocol — official vs community
Official / label
No approved product. ERR agonist with strong mouse exercise-mimetic data (2023); human translation unknown.
Duration: Preclinical only.
The mouse data (25% endurance improvement) drove immediate gray-market appearance.
Community (anecdotal)
50–100 mg oral daily, always paired with training (it's an exercise amplifier, not a replacement, per the theory).
- Cycle:
- 8 weeks.
- Break:
- 4 weeks.
Classic mouse-to-vial pipeline: compelling rodent paper → immediate community dosing.
Human evidence
No controlled human trials exist. Everything known about SLU-PP-332 in humans comes from indirect sources and self-reports.
Preclinical evidence
Preclinical publications 2023–2024 (Univ. of Florida): improved metabolic syndrome in mice.
Known risks
- Unknown in humans.characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- All human pharmacokinetics, safety and efficacy
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.